Hepatitis C attacks the liver. An estimated 20 percent of patients go on to develop cirrhosis, a condition that involves destruction of liver cells.
Patients with hepatitis C who have cirrhosis and abnormally low platelet levels, a disorder known as thrombocytopenia, cannot take the standard drugs for fighting the infection, because these drugs also act to lower platelet counts further. Patients with low platelet counts are also at risk for spontaneous bruising; bleeding in mucosal linings, such as in nose, gums and the gastrointestinal tract; and in severe cases, bleeding in the brain. They are also at greater risk of bleeding at the time of medical procedures.
The new drug, called eltrombopag, works by stimulating cells in the bone marrow to produce more platelets, according to Duke liver specialist John McHutchison, M.D., professor of medicine and the principal investigator for the clinical trial. The trial was of a type called Phase II, which tests the safety and effectiveness of a drug in a small population.
McHutchison presented the results of the trial on Monday, Oct. 30, 2006, at the annual meeting of the American Association for the Study of Liver Disease, in Boston. The trial was supported by GlaxoSmithKline, which developed eltrombopag. McHutchison has received research support from GSK.
To date, physicians have been reluctant to prescribe the standard antihepatitis C drugs called pegylated interferon and ribavirin to patients with advanced liver disease due to hepatitis C and thrombocytopenia because of pegylated interferon's known effect on lowering platelet counts in the blood, McHutchison said.
"When we give these antiviral agents to patients with normal platelet counts, we can cure approximately half of them," McHutchison said. "Eltrombopag increases platelet levels to the point where patients with thrombocytopenia can then be effectively treated with the antiviral therapies. If the promising results we've seen so far in these early clinical trials are borne out in future larger scale registration trials, we will be able to potentially treat many more patients for whom there are currently no options."
The trial enrolled 74 hepatitis C patients with thrombocytopenia. They were randomized to one of four groups: three groups received eltrombopag at doses of 30 milligrams, 50 milligrams or 75 milligrams, and one group received an inactive placebo. All of the patients took the drug daily for four weeks. Patients whose platelet counts rose to a predefined level after four weeks were then started on the standard antiviral treatment.
"We found that 95 percent of the patients who received the highest dose of the new drug responded with increased levels of platelets, and 91 percent of those patients were then able to start antiviral therapy with pegylated interferon and ribavirin," McHutchison said. "After 12 weeks, 61 percent of these patients were still able to maintain antiviral therapy."
The patients receiving the lower doses of the drug also had better responses than those receiving placebo. Three-quarters of the patients taking either 30 milligrams or 50 milligrams of the drug demonstrated increased platelet levels enough to initiate antiviral therapy. In the placebo group, no patients saw this improvement. Fifty-three percent of patients taking the 50 milligram dose were able to complete the 12-week course of antivirals, and 36 percent of those taking 30 milligrams completed the course.
Side effects of the drug -- headache, dry mouth, nausea and diarrhea -- were not clinically worrisome, McHutchison said.
The new drug also may benefit patients who have low platelet counts caused by other liver diseases, particularly those who need to undergo surgery or other invasive procedures that carry a significant risk of bleeding, he said.
McHutchison and other investigators are currently involved in planning larger Phase III clinical trials of eltrombopag to further refine the optimal dosing for the drug and to determine which patients would benefit most from receiving the drug. Phase III trials usually are the final stage before a new drug is introduced to the marketplace.
It is estimated that about 3.9 million Americans are infected with the hepatitis C virus. The virus is most commonly transmitted by injected drug use.
Richard Merritt | EurekAlert!
First time-lapse footage of cell activity during limb regeneration
25.10.2016 | eLife
Phenotype at the push of a button
25.10.2016 | Institut für Pflanzenbiochemie
Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.
This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...
Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion
Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
25.10.2016 | Earth Sciences
25.10.2016 | Power and Electrical Engineering
25.10.2016 | Process Engineering